Project Cure CRC
Request for Proposals
Project Cure CRC has announced a rolling Request for Proposals (RFP), making available tens of millions of dollars to academic and industry researchers whose work aims to expedite colorectal cancer research to a curable science. Download the RFP for details and submit your proposal at ProposalCentral.
Hope for today's patients
With bold and urgent action, Project Cure CRC seeks to cultivate breakthroughs in colorectal cancer diagnosis, treatment, metastasis, and survivorship. The project will ignite innovative treatments to end colorectal cancer now.
Cure CRC Summit
In December 2024, the Cure CRC Summit welcomed more than 100 prominent scientists to foster partnerships that will challenge the status quo of colorectal therapies and discover new trajectories toward a cure.
Support the project
The Colorectal Cancer Alliance invites the public, corporations, foundations, and philanthropic individuals to join us by contributing to Project Cure CRC.
Project Cure CRC Co-Chairs
Michael Sapienza
CEO, Colorectal Cancer Alliance
Katie Chudnovsky
Board Member, Colorectal Cancer AllianceScientific Co-Chairs
John Marshall, MD
Georgetown UniversityScott Kopetz, MD, PhD, FACP
MD Anderson Cancer CenterChristopher Lieu, MD
University of Colorado Cancer CenterPatient Advocate Co-Chair
John Woerner
mCRC Survivor and Board Member, Colorectal Cancer AllianceAlliance Project Lead
David Fenstermacher, PhD
Senior Director of Research and Medical Affairs, Colorectal Cancer AllianceGrant Review Committee
Scott Kopetz, MD, PhD, FACP
MD Anderson Cancer CenterChristopher Lieu, MD
University of Colorado Cancer CenterJohn Marshall, MD
Georgetown University
Top resources
Project Cure CRC Continues to Fuel Urgently Needed Research Funding
The Alliance's Project Cure CRC announces $1.3 million in new research grants — bringing total funding to nearly $12 million — to drive breakthroughs in colorectal cancer care and address critical research gaps.
2025 ASCO update: Six big studies
The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.